Global and India High-end Generic Drug Market Report & Forecast 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global and India High-end Generic Drug Market Report & Forecast 2024-2034
Generic drugs refer to similar drugs developed based on existing original drugs and are usually cheaper than the original drugs. The emergence of high-end generic drugs can effectively reduce patients' medical costs and promote the development of the pharmaceutical industry.
The global High-end Generic Drug revenue was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during the review period (2024-2034).
In India, the High-end Generic Drug revenue is expected to grow from US$ million in 2022 to US$ million by 2029, at a CAGR of % during the forecast period 2024-2034.
As people's demand for medical care increases, pharmaceutical technology advances and the prevalence of chronic diseases increases, and pharmaceutical R&D activities and investments increase, the high-end generic drug industry is developing well. However, the industry also faces various challenges, such as strict market supervision, high research and development costs, expiration of drug patents, and declining revenue. Companies need to continue to innovate and adapt to these challenges to remain competitive in the market. In addition, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for high-end generic pharmaceutical companies to be nimble in responding to emerging public health needs.
This report focuses on global and India High-end Generic Drug market, also covers the segmentation data of other regions in regional level and county level.
India is now the world’s most populous country. According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2024, powered by domestic investment. First and foremost, the key factor in India's rapid economic growth is the huge supply and demand from a large population base. Demand and supply sides working in both directions to support India's economic stability.
India is a market full of opportunities, and the demand for High-end Generic Drug will continue to grow rapidly in the future.
Global High-end Generic Drug Scope and Market Size
High-end Generic Drug market is segmented in regional and country level, by players, by Type and by Application. Companies, stakeholders, and other participants in the global High-end Generic Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2029.
For India market, this report focuses on the High-end Generic Drug market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in India.
Viatris
Teva
Organon
Sun Pharma
Bausch Health
Mylan NV
Novartis AG
Pfizer Inc
Fresenius SE & Co
Lupin Limited
Endo Pharmaceuticals Inc
Aurobindo Pharma Limited
Warner (India) Pharma Private Limited
Shijiazhuang Pharma Group
Fosun Pharma
Yangtze River Pharmaceutical Group
Sichuan KELUN PHARMACEUTICAL Co., Ltd.
Nantong Beite Pharmaceutical Machinery Co.,Ltd
CR Pharmaceutical Group
Segment by Type
Prescription Drugs
Non-prescription Drugs
Hospital
Pharmacy
Others
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter 1Introduces High-end Generic Drug definition, global market size, India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of High-end Generic Drug companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5Revenue of High-end Generic Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6Americas by type, by application and by country revenue for each segment.
Chapter 7EMEA by type, by application and by region, revenue for each segment.
Chapter 8China by type, by application revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, High-end Generic Drug revenue, gross margin and recent development, etc.
Chapter 11Analyst's Viewpoints/Conclusions
The global High-end Generic Drug revenue was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during the review period (2024-2034).
In India, the High-end Generic Drug revenue is expected to grow from US$ million in 2022 to US$ million by 2029, at a CAGR of % during the forecast period 2024-2034.
As people's demand for medical care increases, pharmaceutical technology advances and the prevalence of chronic diseases increases, and pharmaceutical R&D activities and investments increase, the high-end generic drug industry is developing well. However, the industry also faces various challenges, such as strict market supervision, high research and development costs, expiration of drug patents, and declining revenue. Companies need to continue to innovate and adapt to these challenges to remain competitive in the market. In addition, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for high-end generic pharmaceutical companies to be nimble in responding to emerging public health needs.
This report focuses on global and India High-end Generic Drug market, also covers the segmentation data of other regions in regional level and county level.
India is now the world’s most populous country. According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2024, powered by domestic investment. First and foremost, the key factor in India's rapid economic growth is the huge supply and demand from a large population base. Demand and supply sides working in both directions to support India's economic stability.
India is a market full of opportunities, and the demand for High-end Generic Drug will continue to grow rapidly in the future.
Global High-end Generic Drug Scope and Market Size
High-end Generic Drug market is segmented in regional and country level, by players, by Type and by Application. Companies, stakeholders, and other participants in the global High-end Generic Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2029.
For India market, this report focuses on the High-end Generic Drug market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in India.
By Company
Viatris
Teva
Organon
Sun Pharma
Bausch Health
Mylan NV
Novartis AG
Pfizer Inc
Fresenius SE & Co
Lupin Limited
Endo Pharmaceuticals Inc
Aurobindo Pharma Limited
Warner (India) Pharma Private Limited
Shijiazhuang Pharma Group
Fosun Pharma
Yangtze River Pharmaceutical Group
Sichuan KELUN PHARMACEUTICAL Co., Ltd.
Nantong Beite Pharmaceutical Machinery Co.,Ltd
CR Pharmaceutical Group
Segment by Type
Prescription Drugs
Non-prescription Drugs
Segment by Application
Hospital
Pharmacy
Others
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter Introduction
Chapter 1Introduces High-end Generic Drug definition, global market size, India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of High-end Generic Drug companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5Revenue of High-end Generic Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6Americas by type, by application and by country revenue for each segment.
Chapter 7EMEA by type, by application and by region, revenue for each segment.
Chapter 8China by type, by application revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, High-end Generic Drug revenue, gross margin and recent development, etc.
Chapter 11Analyst's Viewpoints/Conclusions
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices